Larry and All more news.
PARACELSIAN ANNOUNCES HEAD OF NEW DRUG DEVELOPMENT DIVISION
ITHACA, NY, February 17, 1999 - Paracelsian, Inc. (PRLN:OTCBB) announced today that Hira Gurtoo,
Ph.D., has been hired to the position of President of its Drug Development Division. Dr. Gurtoo has
served as a Director of Paracelsian (http://www.paracelsian.com) since February 1998.
"Dr. Gurtoo is uniquely qualified to lead the development of this core business unit," said Bernie
Landes, Paracelsian's President and CEO. "Paracelsian's drug development division is an essential
component of the Company's long term success and, for that reason, it requires aggressive
leadership," continued Mr. Landes. "While the dietary supplement quality assurance and product
development business built on BioFIT(tm) and the environmental monitoring business built on the Ah
Immunoassay provide vehicles for reliable and steadily expanding revenue streams, drug development
provides the opportunity for explosive appreciation in the Company's value," concluded Mr. Landes.
Dr. Gurtoo is a renowned cancer research scientist. He retired earlier this month from a senior
position at Roswell Park Cancer Institute in Buffalo, New York. He also was Research Professor of
Pharmacology at State University of New York at Buffalo, where he continues to hold an honorary title.
In addition to having a degree in Veterinary Medicine, Dr. Gurtoo received his Ph.D. in Biochemistry
from Virginia Polytechnic Institute and completed his post-doctoral work at Yale. He has served as a
consultant to the National Academy of Sciences and to the NIH and has been published extensively.
"Paracelsian's drug development strategy will focus on leveraging the Company's existing assets to
create valued added partnerships with major pharmaceutical and diagnostic companies and with
research organizations such as Roswell Park Memorial Cancer Institute and the Southern Research
Institute," said Dr. Gurtoo. "Initially, we will make an effort to secure value added partnerships to
accomplish three goals: 1) development of antiviral therapies based on the Company's Ah receptor
patent and its Andrographolide patent, 2) screening of the Company's herbal extracts and the
development of active extracts into potential therapeutic agents, and 3) evaluation of the Company's
CDK assays as diagnostic and prognostic tools in cancer diagnosis and treatment," added Dr. Gurtoo.
"We believe that success in meeting these short-term goals will enable the Company to generate the
capital necessary for becoming a recognizable player in the pharmaceutical and biotech industry,"
concluded Dr. Gurtoo.
Notice: This news release may contain forward-looking statements. Investors are cautioned that such
forward-looking statements involve risks and uncertainties, including but not limited to, the results of
research and development efforts, the effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive products, product development,
commercialization and technological difficulties, and other risks detailed in the Company's periodic
reports filed with the Securities and Exchange Commission.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing
undue reliance on such statements.
SOURCE: Paracelsian
|
